Stout provided common equity and complex securities valuations to a biotechnology company during its Series A funding. During a period of cost-cutting, the company pivoted to relying upon its cap table management software company for IRC 409A valuations.

Major obstacles on valuation issues and encouragement from auditors led management to come to our team for valuation assistance as the company geared up for an initial public offering (IPO) in 2020. We subsequently performed numerous equity and derivative valuations to support the S-1 filing and IPO.

After becoming a public NASDAQ company, the company repeatedly engaged Stout for quarterly performance award liability valuations under ASC 718.